- Home
- FLZH vs GRI Comparison
FLZH vs GRI Comparison
Compare FLZH & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLZH | GRI |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 3.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FLZH | GRI |
|---|---|---|
| Price | $1.86 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | ★ 131.6K | 91.6K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $0.18 |
| 52 Week High | $2.88 | $6.70 |
Technical Indicators
Market Signals| Indicator | FLZH | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 21.57 | 32.22 |
| Support Level | $1.61 | $1.56 |
| Resistance Level | $1.91 | $2.27 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 21.95 | 10.87 |
Price Performance
Historical ComparisonAbout GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.